A large survey posted by the Bladder Cancer Advocacy Network (BCAN) and
published in UroToday revealed a growing preference for Cysview®.
A survey of 600 bladder cancer patients posted by the Bladder Cancer Advocacy
Network (BCAN) in January revealed a growing preference for Blue Light
Cystoscopy with Cysview. Of the respondents, 438 reported having received
Cysview and said they were diagnosed at one facility, but then went to another
that offers Blue Light Cystoscopy (BLCT) with Cysview.
Read more on UroToday (https://www.urotoday.com/recent-abstracts/urologic
-oncology/bladder-cancer/111331-survey-of-bladder-cancer-patients-reveals-big
-changes-patients-are-looking-for-cysview-hexaminolevulinate.html)